Norway · Delayed Price · Currency is NOK Circio Holding ASA Earnings Call Transcripts
Fiscal Year 2026
-
circVec technology shows robust, reproducible, and highly potent gene expression in heart and eye, with significant dose-sparing and safety advantages. The platform is advancing disease-specific constructs and in vivo CAR applications, supported by strong fundraising and ongoing collaborations.
Fiscal Year 2025
-
circVec technology delivers significantly higher and more durable protein expression than conventional approaches, with strong preclinical results in heart, eye, and CNS models. Lead programs are advancing toward key efficacy milestones, supported by new pharma collaborations and a robust financial position.
-
Strong R&D progress with circVec platform led to up to 44x improved heart expression and 15x in eye, while financial stability was secured through extended Atlas financing. Seven new collaborations and a lean cost structure position the company for further growth and new partnerships.
-
Circular RNA technology is advancing rapidly, with circVec showing strong potential to enhance gene therapy efficacy and safety, especially in muscle, heart, and spleen tissues. Multiple collaborations and secured financing support ongoing R&D and business development, with key milestones ahead.
-
Significant R&D progress includes a 27x improvement with circVec 3.0, successful in vivo delivery to spleen, and up to 50% higher protein expression in AAV vectors. Financially, the company secured NOK 30 million, reduced costs, and extended its financing runway. Key data readouts and potential partnerships are expected in the coming months.
Fiscal Year 2024
-
CircVec 3.0 delivers a major leap in circular mRNA technology, offering up to 27 times higher protein expression and up to 75 times longer half-life than mRNA. The platform is advancing toward gene therapy applications, with muscular dystrophies as initial targets and clinical entry expected within three years.
-
circVec technology demonstrated superior durability and expression over mRNA, with ongoing upgrades and five new research collaborations. Financial position improved by a NOK 70 million loan waiver and a successful rights issue, securing funding until mid-2025.